Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intraperitoneal Aerosolization of Albumin-stabilized Paclitaxel Nanoparticles for Stomach, Pancreas, Breast and Ovarian Cancer

Next Previous
Trial Profile

Intraperitoneal Aerosolization of Albumin-stabilized Paclitaxel Nanoparticles for Stomach, Pancreas, Breast and Ovarian Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Advanced breast cancer; Carcinoma; Gastrointestinal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Acronyms PIPAC-nabpac

    • Most Recent Events

    • 03 Aug 2020 Status changed from recruiting to completed.
    • 24 May 2018 Phase has been changed from I/II to I. Parallel assignment has been changed to single group assignment. treatment arm has been changed. Efficacy endpoint has been removed. Planned patient number has been changed from 70 to 20. Gender has been changed from female to male and female both.
    • 24 May 2018 Planned number of patients changed from 70 to 20.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top